Optimizing Clinical Research and Patient Perceptions of ctDNA Testing

Outcomes favoring robotic surgery for CRC may be influenced by patient selection factors, including clinical stability.

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

An update of phase 1 data from the CTMX-2051-101 study is expected to be available by the first quarter of 2026.

Oncology pharmacist Jagoda Misniakiewicz, PharmD, discusses the potential efficacy and safety profile of fruquintinib in patients with metastatic CRC.

Data from the phase 3 BEACON CRC trial support the approval of encorafenib plus cetuximab for this colorectal cancer population in China.

The FDA has waived the need for a botensilimab monotherapy arm in the phase 3 BATTMAN trial evaluating the combination in MSS metastatic colorectal cancer.